Unknown

Dataset Information

0

Chronic hepatitis B virus infection is associated with a poorer prognosis in diffuse large B-cell lymphoma: a meta-analysis and systemic review.


ABSTRACT: Accumulating evidence from clinical trials indicates chronic hepatitis B virus (HBV) infection is associated with the incidence of diffuse large B-cell lymphoma (DLBCL) and may be associated with the prognosis of DLBCL, though this suggestion remains controversial. We performed a meta-analysis to assess whether HBV infection is associated with prognosis and response to chemotherapy in DLBCL. After a strict literature search strategy, a total of 809 HBV surface antigen (HBsAg) seropositive patients with DLBCL and 2849 HBsAg seronegative patients with DLBCL from twelve trials were included. DLBCL patients with chronic HBV infection had significantly poorer 2- and 5-year overall survival (OS) (HR 1.54, 95% CI 1.23-1.92, P<0.001 and 1.79, 1.48-2.17, P<0.001) and 2- and 5-year progression-free survival (PFS) (HR 1.44, 95% CI 1.14-1.81, P=0.002 and HR 1.34, 95% CI 1.02-1.75, P=0.03). HBsAg-seronegative patients also had a lower complete response (CR) rate (OR 0.48, 95% CI 0.34-0.68, P<0.001), higher progressive disease (PD) rate (OR 2.08, 95% CI 1.34-3.24, P=0.001), and more advanced clinical features. This meta-analysis indicates HBV infection leads to a poorer prognosis and poorer response to standard chemotherapy.

SUBMITTER: Rong X 

PROVIDER: S-EPMC6603406 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6575146 | BioStudies
2020-01-01 | S-EPMC7485358 | BioStudies
1000-01-01 | S-EPMC4396049 | BioStudies
1000-01-01 | S-EPMC4694815 | BioStudies
1000-01-01 | S-EPMC6004660 | BioStudies
2019-01-01 | S-EPMC6500223 | BioStudies
2019-01-01 | S-EPMC6530193 | BioStudies
2019-01-01 | S-EPMC6422518 | BioStudies
2018-01-01 | S-EPMC6292058 | BioStudies
2016-01-01 | S-EPMC4980030 | BioStudies